When do the HYPAQUE-CYSTO patents expire, and when will generic HYPAQUE-CYSTO be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	HYPAQUE-CYSTO	diatrizoate meglumine	SOLUTION;URETHRAL	016403-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

HYPAQUE-CYSTO, a contrast agent used in diagnostic imaging, presents a complex investment scenario driven by patent exclusivity, market demand, and regulatory approvals. This analysis examines the drug's current standing, intellectual property protection, and future market potential.

What is HYPAQUE-CYSTO and Its Therapeutic Use?

HYPAQUE-CYSTO is an iodinated contrast medium. It is administered intravenously for urography, computed tomography (CT) of the abdomen and pelvis, and angiography. The compound's radio-opacity allows it to visualize the urinary tract and vascular structures under X-ray. The primary indication is for diagnostic imaging where visualization of these areas is medically necessary.

What is the Current Market Status of HYPAQUE-CYSTO?

HYPAQUE-CYSTO is a mature product with established market penetration. Its sales are primarily driven by the demand for diagnostic imaging procedures that utilize X-ray technology. Market volume is influenced by the number of urological and vascular diagnostic procedures performed globally. Competition exists from other contrast agents, both iodinated and non-iodinated, as well as alternative imaging modalities.

The global contrast media market, encompassing both X-ray and MRI contrast agents, was valued at approximately USD 5.8 billion in 2022 and is projected to grow, driven by increasing diagnostic imaging procedures and the prevalence of chronic diseases requiring advanced imaging. (Source: Grand View Research, 2023). Within this, iodinated contrast media for X-ray procedures constitutes a significant segment.

What is the Intellectual Property Landscape for HYPAQUE-CYSTO?

The intellectual property surrounding HYPAQUE-CYSTO primarily revolves around its composition of matter and manufacturing processes. Original patents for the core compound have long since expired. However, secondary patents related to specific formulations, delivery systems, or novel uses may still be in effect or have recently expired.

For HYPAQUE-CYSTO (diatrizoate meglumine and diatrizoate sodium solution), the foundational patents have expired. However, patent protection can extend to specific formulations, purity standards, or improved manufacturing methods. A thorough patent search is required to identify any remaining active patents. For instance, patents related to specific viscosity modifiers or stabilizers in the formulation could provide a limited period of protection even after the compound patent has lapsed.

Key Patent Considerations:

Composition of Matter Patents: These are the strongest but oldest patents. For HYPAQUE-CYSTO's core active ingredients, these are expired.
Process Patents: These protect specific methods of manufacturing the drug. Such patents, if still active, can prevent competitors from using the same efficient production techniques.
Formulation Patents: These protect specific combinations of active ingredients with excipients, or novel delivery mechanisms. These can offer protection for specific product variations.
Method of Use Patents: These patents cover the use of the drug for a particular medical indication. Expired or soon-to-expire method of use patents can open the door for generic competition or new therapeutic applications by other companies.

Patent Expiry Projections:

Analysis of patent databases (e.g., USPTO, EPO) reveals that the primary composition of matter patents for diatrizoate salts have expired.
While specific formulation or process patents may have existed, identifying the exact expiry dates for these secondary patents without a dedicated patent landscaping report is challenging. However, given the drug's established presence, it is likely that most significant patent protection has elapsed or is nearing expiry.

What is the Competitive Landscape for HYPAQUE-CYSTO?

The market for iodinated contrast media is competitive. Key competitors include established pharmaceutical companies and generic manufacturers.

Major Competitors and Products:

Bayer AG: Produces various iodinated contrast agents, including iohexol (Omnipaque) and iopamidol (Isovue). These are widely used and represent significant competition.
GE Healthcare: Offers a portfolio of contrast agents, including iodinated products used in CT and X-ray imaging.
Bracco Imaging S.p.A.: A major player in the contrast media market, with a range of iodinated and gadolinium-based agents.
Generic Manufacturers: Companies specializing in generic pharmaceuticals are likely to offer bioequivalent versions of HYPAQUE-CYSTO once patent protection fully lapses.

The competitive advantage of HYPAQUE-CYSTO relies on its established safety profile, efficacy, cost-effectiveness, and existing distribution channels. However, newer contrast agents may offer improved safety profiles (e.g., lower osmolality, reduced nephrotoxicity) or enhanced imaging characteristics, posing a threat.

What are the Regulatory Considerations for HYPAQUE-CYSTO?

HYPAQUE-CYSTO is subject to stringent regulatory oversight by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Regulatory compliance is critical for market access and continued sales.

Key Regulatory Aspects:

Drug Approval: The drug has received marketing authorization in major global markets.
Manufacturing Standards: Production facilities must adhere to Good Manufacturing Practices (GMP).
Post-Market Surveillance: Ongoing monitoring for adverse events and pharmacovigilance is required.
Labeling and Packaging: Regulatory requirements for product information and patient safety.
Generic Approvals: The pathway for generic versions involves demonstrating bioequivalence to the reference listed drug. This typically requires Abbreviated New Drug Applications (ANDAs) in the U.S.

The regulatory environment can impact market entry for generics and potentially lead to product recalls or labeling changes if safety concerns arise.

What is the Market Potential and Growth Outlook for HYPAQUE-CYSTO?

The market for HYPAQUE-CYSTO is influenced by several macroeconomic and healthcare trends.

Market Drivers:

Aging Population: An increasing elderly population leads to a higher prevalence of diseases requiring diagnostic imaging.
Advancements in Imaging Technology: The widespread adoption of CT and X-ray scanners increases demand for contrast agents.
Growing Incidence of Chronic Diseases: Conditions such as cardiovascular disease, cancer, and kidney disease often necessitate diagnostic imaging.
Emerging Markets: Increasing healthcare infrastructure and access to diagnostic services in developing economies.

Market Challenges:

Competition from Newer Agents: Development of contrast agents with improved safety profiles or superior imaging capabilities.
Price Pressure: The market for mature drugs often faces significant price erosion, especially with the advent of generics.
Concerns about Nephrotoxicity: Iodinated contrast media can pose risks to patients with pre-existing kidney conditions, leading to a preference for alternative agents or imaging modalities in certain cases.
Shifting Diagnostic Modalities: Growth in MRI and PET imaging may, in some applications, reduce reliance on X-ray-based contrast agents.

The growth outlook for HYPAQUE-CYSTO is likely to be modest, characterized by steady demand in established markets but facing pressure from generics and newer technologies. Differentiation through cost or specific niche applications will be critical.

What are the Financial Considerations and Investment Risks?

The investment scenario for HYPAQUE-CYSTO involves evaluating its revenue streams against associated costs and market risks.

Financial Metrics to Consider:

Revenue: Sales generated from the sale of HYPAQUE-CYSTO. This is influenced by market share, pricing, and sales volume.
Cost of Goods Sold (COGS): Manufacturing, raw material, and packaging costs.
Operating Expenses: Research and development (if any ongoing for new formulations), marketing, sales, and administrative costs.
Profit Margins: Gross and net profit margins. Mature products often have stable but potentially declining margins due to pricing pressure.

Investment Risks:

Generic Competition: The expiry of remaining patents will likely lead to significant price erosion as generic versions enter the market.
Technological Obsolescence: Development of superior imaging techniques or contrast agents could reduce the demand for HYPAQUE-CYSTO.
Regulatory Changes: New safety regulations or requirements could increase compliance costs or restrict usage.
Litigation: Patent disputes or product liability claims can arise.
Market Share Erosion: Competitors introducing more cost-effective or technologically advanced products.
Supply Chain Disruptions: Sourcing of raw materials or manufacturing interruptions.

What is the Strategic Outlook for HYPAQUE-CYSTO Stakeholders?

Stakeholders in HYPAQUE-CYSTO, whether manufacturers or investors, must adopt strategies that acknowledge the drug's lifecycle stage.

Strategic Considerations:

Cost Optimization: Focus on efficient manufacturing and supply chain management to maintain profitability in a competitive, price-sensitive market.
Market Segmentation: Identify and focus on specific geographic regions or patient populations where HYPAQUE-CYSTO retains a competitive advantage (e.g., cost-sensitive markets, specific indications).
Lifecycle Management: Explore opportunities for minor formulation improvements or combination therapies that could extend product relevance, though significant R&D investment is unlikely for such a mature product.
Divestiture or Acquisition: For companies holding HYPAQUE-CYSTO, a strategic divestiture to a company focused on mature generics or a portfolio consolidation might be considered. For investors, acquiring rights to a mature product with established cash flow can be attractive if the entry price is aligned with its diminishing exclusivity.
Generic Manufacturing Strategy: For companies with the capability, developing and launching generic versions of HYPAQUE-CYSTO presents an opportunity to capture market share post-patent expiry.

The long-term strategy for HYPAQUE-CYSTO will likely involve managing its decline in exclusivity and maximizing cash flow from its remaining market presence, rather than significant growth initiatives.

Key Takeaways

HYPAQUE-CYSTO is an established iodinated contrast agent for diagnostic imaging.
Primary composition of matter patents have expired, increasing the likelihood of generic competition.
The competitive landscape is populated by major pharmaceutical companies and emerging generic manufacturers.
Regulatory compliance remains a critical factor for market access and operation.
Market growth is influenced by an aging population and diagnostic technology adoption, but faces headwinds from newer agents and price pressure.
Investment risks are significant due to patent expiry, potential technological obsolescence, and price erosion.
Strategic focus for stakeholders should be on cost optimization, market segmentation, and managing the product’s lifecycle rather than growth.

Frequently Asked Questions

When did the primary patents for HYPAQUE-CYSTO expire? The foundational composition of matter patents for diatrizoate salts, the active ingredients in HYPAQUE-CYSTO, have expired. Specific expiry dates for secondary formulation or process patents would require a detailed patent landscaping report.
What are the main risks associated with investing in HYPAQUE-CYSTO? The primary risks include significant price erosion due to generic competition following patent expiry, potential obsolescence from newer imaging technologies or contrast agents, and ongoing regulatory compliance requirements.
How does HYPAQUE-CYSTO compare to newer contrast agents? Newer agents may offer advantages such as lower osmolality, reduced nephrotoxicity, or improved imaging characteristics. HYPAQUE-CYSTO's advantages typically lie in its established cost-effectiveness and long history of use.
What is the typical lifespan of an iodinated contrast agent after patent expiry? After patent expiry, an iodinated contrast agent's lifespan is characterized by declining sales and market share as generic competitors enter the market, leading to significant price reductions. Its continued use depends on its cost-effectiveness and specific clinical utility in certain niches.
What are the implications of Good Manufacturing Practices (GMP) for HYPAQUE-CYSTO? Adherence to GMP is mandatory for the production of HYPAQUE-CYSTO. It ensures product quality, safety, and consistency. Non-compliance can lead to regulatory action, product recalls, and loss of market authorization.

Citations

[1] Grand View Research. (2023). Contrast Media Market Size, Share & Trends Analysis Report By Type (X-ray/CT, MRI, Ultrasound), By Product (Iodinated, Gadolinium-Based, Barium-Based), By Application, By End-use, And By Region, Segment Forecasts, 2023 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/contrast-media-market

HYPAQUE-CYSTO Drug Patent Profile

When do Hypaque-cysto patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for HYPAQUE-CYSTO

US Patents and Regulatory Information for HYPAQUE-CYSTO

HYPAQUE-CYSTO: Investment Fundamentals and Patent Landscape Analysis